Patrick N Harter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/253729/publications.pdf

Version: 2024-02-01

90 papers 4,780 citations

29 h-index

172457

64 g-index

90 all docs

90 docs citations

90 times ranked 10339 citing authors

#	Article	IF	CITATIONS
1	The Acute Superficial Siderosis Syndrome — Clinical Entity, Imaging Findings, and Histopathology. Cerebellum, 2023, 22, 296-304.	2.5	5
2	The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis. Neuro-Oncology, 2022, 24, 213-225.	1.2	36
3	Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial. European Journal of Nutrition, 2022, 61, 477-487.	3.9	16
4	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. Acta Neuropathologica Communications, 2022, 10, 5.	5.2	12
5	Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma. Neurology, 2022, 98, .	1.1	2
6	HIP1R and Vimentin immunohistochemistry predict $1\text{p}/19\text{q}$ status in IDH-mutant glioma. Neuro-Oncology, 2022, , .	1.2	4
7	Linking epigenetic signature and metabolic phenotype in <i>IDH</i> mutant and <i>IDH</i> wildtype diffuse glioma. Neuropathology and Applied Neurobiology, 2021, 47, 379-393.	3.2	4
8	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of <i>EGFR</i> . Neuro-Oncology, 2021, 23, 34-43.	1.2	75
9	Neurotoxicity of subarachnoid Gd-based contrast agent accumulation: a potential complication of intraoperative MRI?. Neurosurgical Focus, 2021, 50, E12.	2.3	6
10	Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients. Journal of Molecular Histology, 2021, 52, 233-243.	2.2	8
11	A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2373-2383.	2.5	2
12	Postoperative outcomes and surgical ratio at a newly established epilepsy center: The first 100 procedures. Epilepsy and Behavior, 2021, 116, 107715.	1.7	3
13	Meningioma Surgery in Patients ≥70 Years of Age: Clinical Outcome and Validation of the SKALE Score. Journal of Clinical Medicine, 2021, 10, 1820.	2.4	5
14	TGFâ€Î² activates pericytes via induction of the epithelialâ€toâ€mesenchymal transition protein SLUG in glioblastoma. Neuropathology and Applied Neurobiology, 2021, 47, 768-780.	3.2	6
15	CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis. International Journal of Molecular Sciences, 2021, 22, 6993.	4.1	26
16	AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Na $ ilde{A}^-$ ve and Treatment-Resistant Leukemia. Cancer Discovery, 2021, 11, 2924-2943.	9.4	20
17	DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma., 2021, 9, e002226.		26
18	Clinical Outcome and Risk Factors of Red Blood Cell Transfusion in Patients Undergoing Elective Primary Meningioma Resection. Cancers, 2021, 13, 3601.	3.7	8

#	Article	IF	CITATIONS
19	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathologica, 2021, 142, 827-839.	7.7	33
20	Persistent bowel dysfunction after surgery for Hirschsprung's disease: A neuropathological perspective. World Journal of Gastrointestinal Surgery, 2021, 13, 822-833.	1.5	1
21	Early and Late Postoperative Seizures in Meningioma Patients and Prediction by a Recent Scoring System. Cancers, 2021, 13, 450.	3.7	13
22	Genetic and epigenetic characterization of posterior pituitary tumors. Acta Neuropathologica, 2021, 142, 1025-1043.	7.7	7
23	High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma. Pathology Research and Practice, 2020, 216, 152728.	2.3	8
24	Maintenance of Energy Homeostasis during Calorically Restricted Ketogenic Diet and Fasting-MR-Spectroscopic Insights from the ERGO2 Trial. Cancers, 2020, 12, 3549.	3.7	9
25	Activation of Epidermal Growth Factor Receptor Sensitizes Glioblastoma Cells to Hypoxia-Induced Cell Death. Cancers, 2020, 12, 2144.	3.7	6
26	Infratentorial IDH-mutant astrocytoma is a distinct subtype. Acta Neuropathologica, 2020, 140, 569-581.	7.7	45
27	Mid-Gestation lethality of Atxn2l-Ablated Mice. International Journal of Molecular Sciences, 2020, 21, 5124.	4.1	13
28	Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer. Cancers, 2020, 12, 3050.	3.7	1
29	Cholinergic innervation and ganglion cell distribution in Hirschsprung's disease. BMC Pediatrics, 2020, 20, 399.	1.7	7
30	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathologica, 2020, 140, 409-413.	7.7	116
31	ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma. International Journal of Radiation Oncology Biology Physics, 2020, 108, 987-995.	0.8	46
32	Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. Journal of Clinical Investigation, 2020, 130, 2488-2495.	8.2	23
33	Blood Pressure Lowering Decreases Intracerebral Hemorrhage Volume and Improves Behavioral Outcomes in Experimental Animals. Journal of Stroke, 2020, 22, 416-418.	3.2	1
34	MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathologica, 2019, 138, 1075-1089.	7.7	104
35	IGF1R Is a Potential New Therapeutic Target for HGNET-BCOR Brain Tumor Patients. International Journal of Molecular Sciences, 2019, 20, 3027.	4.1	17
36	Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. Cancer Immunology Research, 2019, 7, 1910-1927.	3.4	74

#	Article	IF	Citations
37	Impact of Docetaxel on blood-brain barrier function and formation of breast cancer brain metastases. Journal of Experimental and Clinical Cancer Research, 2019, 38, 434.	8.6	11
38	Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor. International Journal of Molecular Sciences, 2019, 20, 4267.	4.1	10
39	Influence of pregnancy on glioma patients. Acta Neurochirurgica, 2019, 161, 535-543.	1.7	11
40	Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma. Cancer Research, 2019, 79, 2298-2313.	0.9	56
41	Lack of H3K27 trimethylation is associated with $1p/19q$ codeletion in diffuse gliomas. Acta Neuropathologica, 2019, 138, 331-334.	7.7	22
42	Therapeutic Targeting of Stat3 Using Lipopolyplex Nanoparticle-Formulated siRNA in a Syngeneic Orthotopic Mouse Glioma Model. Cancers, 2019, 11, 333.	3.7	22
43	The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma. British Journal of Cancer, 2019, 120, 481-487.	6.4	45
44	Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients. Journal of Clinical Medicine, 2019, 8, 2031.	2.4	23
45	Disruption of peroxisome proliferator–activated receptor γ coactivator (PGC)-1α reverts key features of the neoplastic phenotype of glioma cells. Journal of Biological Chemistry, 2019, 294, 3037-3050.	3.4	18
46	Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma. Neuro-Oncology, 2019, 21, 326-336.	1.2	18
47	Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas. Brain Pathology, 2019, 29, 513-529.	4.1	99
48	Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas. Neurosurgery, 2019, 84, 190-197.	1.1	59
49	Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathologica, 2018, 135, 955-963.	7.7	109
50	New MR perfusion features in primary central nervous system lymphomas: pattern and prognostic impact. Journal of Neurology, 2018, 265, 647-658.	3.6	11
51	Tumorigenic and Antiproliferative Properties of the TALE-Transcription Factors MEIS2D and MEIS2A in Neuroblastoma. Cancer Research, 2018, 78, 1935-1947.	0.9	11
52	Dexamethasone-induced leukocytosis is associated with poor survival in newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2018, 137, 503-510.	2.9	37
53	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
54	"Two is not enough―– Impact of the number of tissue samples obtained from stereotactic brain biopsies in suspected glioblastoma. Journal of Clinical Neuroscience, 2018, 47, 311-314.	1.5	13

#	Article	IF	Citations
55	Suppression of oxidative phosphorylation confers resistance against bevacizumab in experimental glioma. Journal of Neurochemistry, 2018, 144, 421-430.	3.9	8
56	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. Acta Neuropathologica, 2018, 136, 975-978.	7.7	11
57	Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems. International Journal of Molecular Sciences, 2018, 19, 1504.	4.1	25
58	Ventriculoperitoneal Shunts Equipped with On-Off Valves for Intraventricular Therapies in Patients with Communicating Hydrocephalus due to Leptomeningeal Metastases. Journal of Clinical Medicine, 2018, 7, 216.	2.4	7
59	Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma. Acta Neuropathologica Communications, 2018, 6, 81.	5.2	22
60	Pericytes/vessel-associated mural cells (VAMCs) are the major source of key epithelial-mesenchymal transition (EMT) factors SLUG and TWIST in human glioma. Oncotarget, 2018, 9, 24041-24053.	1.8	8
61	The angiogenic switch leads to a metabolic shift in human glioblastoma. Neuro-Oncology, 2017, 19, now175.	1.2	50
62	ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors. Oncology Letters, 2017, 14, 5443-5451.	1.8	6
63	Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. Oncology Letters, 2017, 14, 1141-1146.	1.8	58
64	Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death. Brain, 2017, 140, 2623-2638.	7.6	30
65	Neurovascular EGFL7 regulates adult neurogenesis in the subventricular zone and thereby affects olfactory perception. Nature Communications, 2017, 8, 15922.	12.8	24
66	Bevacizumab for Patients with Recurrent Multifocal Glioblastomas. International Journal of Molecular Sciences, 2017, 18, 2469.	4.1	12
67	Effects of soluble CPE on glioma cell migration are associated with mTOR activation and enhanced glucose flux. Oncotarget, 2017, 8, 67567-67591.	1.8	11
68	Classification of meningiomasâ€"advances and controversies. Chinese Clinical Oncology, 2017, 6, S2-S2.	1.2	66
69	Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. Oncology Reports, 2017, 38, 3291-3296.	2.6	46
70	Endothelial cellâ€derived angiopoietinâ€2 is a therapeutic target in treatmentâ€naive and bevacizumabâ€resistant glioblastoma. EMBO Molecular Medicine, 2016, 8, 39-57.	6.9	140
71	Perfusion MRI in the Evaluation of Suspected Glioblastoma Recurrence. Journal of Neuroimaging, 2016, 26, 116-123.	2.0	35
72	Brain invasion in otherwise benign meningiomas does not predict tumor recurrence. Acta Neuropathologica, 2016, 132, 479-481.	7.7	54

#	Article	IF	Citations
73	Downstream effects of plectin mutations in epidermolysis bullosa simplex with muscular dystrophy. Acta Neuropathologica Communications, 2016, 4, 44.	5.2	35
74	BACE-1 is expressedÂin the blood–brain barrier endothelium and is upregulated in a murine model of Alzheimer's disease. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 1281-1294.	4.3	53
75	Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas. Neuro-Oncology, 2016, 18, 173-183.	1.2	35
76	ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. Journal of the National Cancer Institute, 2016, 108, .	6.3	282
77	C5b-9 deposits on endomysial capillaries in non-dermatomyositis cases. Neuromuscular Disorders, 2016, 26, 283-291.	0.6	10
78	Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors. PLoS ONE, 2015, 10, e0127123.	2.5	15
79	Expression Profile of Sonic Hedgehog Pathway Members in the Developing Human Fetal Brain. BioMed Research International, 2015, 2015, 1-15.	1.9	10
80	ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment. BioMed Research International, 2015, 2015, 1-10.	1.9	10
81	<scp>MIF</scp> Receptor <scp>CD</scp> 74 is Restricted to Microglia/Macrophages, Associated with a <scp>M</scp> 1â€Polarized Immune Milieu and Prolonged Patient Survival in Gliomas. Brain Pathology, 2015, 25, 491-504.	4.1	90
82	\hat{l}^2 -Catenin-Gli1 interaction regulates proliferation and tumor growth in medulloblastoma. Molecular Cancer, 2015, 14, 17.	19.2	51
83	<scp>P</scp> aired box gene 8 (<scp>PAX8</scp>) expression is associated with sonic hedgehog (<scp>SHH</scp>)/wingless int (<scp>WNT</scp>) subtypes, desmoplastic histology and patient survival in human medulloblastomas. Neuropathology and Applied Neurobiology, 2015, 41, 165-179.	3.2	4
84	Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathologica, 2015, 129, 115-131.	7.7	122
85	Perioperative cerebral ischemia promote infiltrative recurrence in glioblastoma. Oncotarget, 2015, 6, 14537-14544.	1.8	27
86	Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Oncotarget, 2015, 6, 40836-40849.	1.8	106
87	Netrin-1 Expression Is an Independent Prognostic Factor for Poor Patient Survival in Brain Metastases. PLoS ONE, 2014, 9, e92311.	2.5	28
88	Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma. Neurology, 2014, 83, 227-234.	1.1	28
89	Hypoxia Enhances the Antiglioma Cytotoxicity of B10, a Glycosylated Derivative of Betulinic Acid. PLoS ONE, 2014, 9, e94921.	2.5	13
90	Antiâ€tissue factor (<scp>TF9â€10H10</scp>) treatment reduces tumor cell invasiveness in a novel migratory glioma model. Neuropathology, 2013, 33, 515-525.	1.2	13